Up next! ☀️📚 We're going Sci-fi with the creation on chimeras to prevent transplant rejection 🧑‍🔬Join us 9/30/25. #NephJC Induction of immune tolerance in living related human leukocyte antigen-matched kidney transplantation: A phase 3 randomized clinical trial - PubMed

T4e 5️⃣Primary aldosteronism screening – screen all adults with resistant HTN regardless of potassium level (COR I, LOE B-NR). Continue most antihypertensives except MRA before testing (COR I, LOE C-EO). 📝Is screening worthwhile or should we just be using MRAs earlier? #NephJC

Hi! Cristina Popa, Romanian nephrologist 👋 ✨No COI, 4 am- as a chronic insomniac, I guess I have high risk for HTN #nephjc Just lurking, starting my 28h travel until get to my holiday destination ✈️🚂🚌

❤️Check out the VA for the discussion on the AHA/ACC Hypertension Guidelines 9/16/25 at 9pm EST by @sejalplakhani.bsky.social #NephJC #NephSky #MedSky www.nephjc.com/news/2025/9/ahaacc-htnguide

Change is in the Autumn air 🌬️🍂 Join use only on #Bluesky on 9/16/25 at 9pm EST. We're discussing the 2025 ACC/AHA Hypertension Guideline Update. 🫀🫘🧠 #NephSky #MedSky www.nephjc.com/news/accaha2025-klno3

Rodby, @annagaddy.bsky.social @nephroseeker.medsky.social @juancarlosqvelez.bsky.social and moi voice our views on Twitter versus BlueSky for nephrology folks good points all around and sadness at the fragmentation www.docwirenews.com/post/5-nephr... on @nephtimes.bsky.social #NephSky

Kristen Tillquist, @nephrosage.bsky.social, me, and Susie Hu wrote this onconephrology topic for AJKD Core Curriculum www.sciencedirect.com/science/arti...

‘The simplicity of the NNT is deceptive and can lead to misinterpretation’ Excellent overview and discussion in @ndt-era.bsky.social academic.oup.com/ndt/advance-... #OpenAccess I would add: it *does* lead to misinterpretation and should not be used. #EpiSky #NephSky

The #NephJC version of this here www.nephjc.com/news/2020/10... from @manasib33.bsky.social #JustSayNo to NNT The way CV and Kidney Trialists are using NNT in their presentations and papers is disappointing

From our own @nephroseeker.medsky.social, ACHIEVE-ing lemonade out of possible lemons (a negative study). 🍋

Last #NephJC we discussed the ACHIEVE trial: spironolactone in ESRD patients to decrease cardiovascular outcomes. #TenPostNephJC #NephSky Read the article 👇 pubmed.ncbi.nlm.nih.gov/40818850/

Unlike most pathogenesis reviews which have multidirectional arrows or hypothesis based on 🐁 data This @ndt-era.bsky.social review uses data from completed and ongoing trials to explain what we know about IgAN academic.oup.com/ndt/advance-... #NephSky #OpenAccess

Blood moon (total lunar eclipse) and me on call. Wonder what can go wrong? 🌕🐺🐺 The answer: plenty. After all, we are in Romania , the lad of 🧛 🤷‍♀️ #NephSky

New in #ASNJASN: an epigenetic CRISPR Screen was used for the first time to identify critical genes and pathways involved in vascular calcification. kidney.pub/JASN0793

🤔 How often is end-stage kidney disease in patients with MCD/ FSGS? #NephSky #MedSky @brianrifkin.bsky.social dissected the conclusions from the RaDar study in this #NephJCshorts *the original article from @asnpublications.bsky.social www.nephjc.com/news/nephjc-...

New in #ASNJASN and at #Hypertension25: In a randomized, double-blind, placebo-controlled trial, Baxdrostat reduced systolic blood pressure in patients with CKD and uncontrolled hypertension. Read more about its safety and efficacy in patients with CKD here: kidney.pub/JASN0849

Thoughtful and controversial blog from Last Month in Nephrology #NephSky #MedSy Albuminuria as an ESKD surrogate may be a statistical mirage, limited by imprecision and overinterpretation However, it moved nephrology forward and made studies happen lastmonthinnephrology.wordpress.com

#Medsky #Nephsky 👇👇 Great thread highlighting confounders and reverse causation

🎨 No olviden revisar la versión en español traducida por @dramiliflores.bsky.social #NephJC

And stayed tuned for some secondary papers in addition to the ones already published on run-in adherence assessment (study within a trial) and heart failure event definitions in dialysis RCTs (meta-epidemiological)

Late to the party but important takeaways: large publically funded international trials are feasible in dialysis, run-ins are great, low dose spironolactone is safe and consider it’s use in HFrEF in dialysis or PD for low K+ or for volume, we don’t believe the sex subgroup analysis #NephJC

Finally, the concurrent results of the ALCHEMIST trial (www.sciencedirect.co...) also showed that spironolactone did not reduce major cardiovascular events in older, high-risk hemodialysis patients. #NephJC Infographic by @nephroseeker.medsky.socia

Up next! New AHA/ACC hypertension guidelines #NephJC @ahascience.bsky.social @accintouch.bsky.social

T3f: What’s a nephrologist to do?? If we are powerless to prevent excess CV mortality and hospitalizations in patients on dialysis then the real answer likely lies in dialysis prevention & early initiation of the pillars of CKD treatment. #NephJC www.mdpi.com/1999-49...

And ALCHEMIST had way lower hyperkalemia (they used a lot of K binders, about 45% at baseline!) - see @nephroseeker.medsky.social VA Despite that there was no benefit! www.nephjc.com/news/2025/ne... #NephJC

You got it. Pragmatic choice. Equivalent dose in ESRD to that used in CV studies. Most common dose used in prior trials in ESRD. #NephJC

T0a: Welcome to #NephJC. Tonight, we start with just a brief recap of the RAAS system. As a nephrologist, day- in-and-day out, we try to block components of the RAAS to control proteinuria/end-organ damage #NephJC

Join us 9/2/25 at 9pm EST. We will discuss the use of spironolactone in patients on dialysis to prevent t cardiovascular outcomes and heart failure hospitalizations. Invite your friends. #NephJC #NephSky www.nephjc.com/news/achieve

Excellent summary of the ACHIEVE trial from @drsaivani.bsky.social & @thekidneywhisperer.bsky.social #NephJC chat tomorrow www.nephjc.com/news/achieve

#ESCCongressVisuals from Hot Line 3👇 #ESCCongress

In #HFrEF, quadruple therapy (ARNi, β-blockers, MRA, #SGLT2i) improves survival. Adding #vericiguat may offer a modest ~0.7-year gain, though findings are exploratory, as they are derived from a secondary endpoint of a single trial https://bit.ly/4mE83Rp #JACC #ESCCongress #WCCardio

Digitoxin + GDMT reduced the risk of a composite of all-cause death and hospitalization for worsening #HeartFailure among patients with advanced HF and HFrEF, based on findings from the DIGIT-HF trial presented at #ESCCongress. Read the news story🔗 https://bit.ly/4oZmnp0

I've never seen this figure or sentiment before. But it makes me want to vomit. The intro and discussion are the least important parts of the paper. Methods rule. Results are meaningless without clear and logical methods. If a mentor suggests this, find a better mentor. x.com/acagamic/sta...

In an open-label Phase 2 trial, oxylanthanum carbonate (OLC), a phosphate binder, was well tolerated and enabled serum phosphate concentration control in over 90% of patients with hyperphosphatemia and a low pill burden. Read more in #ASNCJASN: kidney.pub/CJASN0780

Anrikefon (previously known as HSK21542) aka difelikefalin cousin, and itching @kidneyboy.bsky.social choice of #KidneyWk draft now in the @bmj.com www.bmj.com/content/390/... #NephSky #Pruritis

After 2 on calls in 4 days, relax time… 🗺️Finishing 📚 for tomorrow’s #NephJC bookclub Any favorite quote?

It's finally here!! #NephJC summer book club 📚 Everything is Tuberculosis by @johngreensbluesky.bsky.social 8/19/25 @ 9pm EST Come for the discussion, stay for stories. www.nephjc.com/news/2025/8/...

Everything is Tuberculosis ✍️&🎙️ John Green @johngreensbluesky.bsky.social #NephJC 📚 #NephJCBookClub #NephJCSummerBookClub 👉 www.nephjc.com/news/2025/6/... @nephroseeker.medsky.social @brianrifkin.bsky.social @kidneyboy.bsky.social @hswapnil.medsky.social

Join the WCN'26 Social Media Team 🌏 Help deliver dynamic online coverage from Yokohama, Japan 🎥✍️💬 📅 Apply by: Dec 15, 2025 ✅ Perks: Free registration, official recognition, certificate, Spotlight Stage opportunity 🔗 lite.spr.ly/6005KkAF #NephTwitter #MedTwitter #SoMe #ISNWCN

The new @ahascience.bsky.social hypertension guidelines www.ahajournals.org/doi/10.1161/... From @jordybc.bsky.social @daichishimbo.bsky.social and team Coming soon to a #NephJC

Spironolactone does not work for dialysis ACHIEVE published in @thelancet.com @lastwalsh.bsky.social and colleagues www.thelancet.com/journals/lan... Coming soon to a #NephJC near you

When to use spironolactone, eplerenone or finerenone in the spectrum of cardiorenal diseases doi.org/10.1093/ndt/...

🚨 Applications are NOW OPEN for the 4th cohort of the @theisn.org Emerging Leaders Program! 🌍 Build leadership skills 🤝 Collaborate with global experts 🫘 Shape the future of kidney health 🗓️ Apply by Sept 15 🔗 Learn more: www.theisn.org/in-action/gr... #ThisIsISN

Latest episode of @freelyfiltered.bsky.social is live! This one on the two RCTs of DDAVP to prevent renal biopsy bleeding. We had special guest Vandana Niyyar join us. @medpeedskidneys.bsky.social @captainchloride.bsky.social www.nephjc.com/freelyfilter...

1/10 Last #NephJC we discussed HiLo: Hi vs Lo phos targets in HD patients #TenPostNephJC Can restricted diets & loading patients full of phos binders be filed under “Things We Do For No Reason,” or do we finally have proof these measures save lives? pubmed.ncbi.nlm.nih.gov/40638247/

Can we start on our nominations? @danieledmonston.bsky.social for most engaged scientist for #NephJCKidneys!

If you want to support #NephJC and get some cool merch, check out www.nephjc.com/merch...#NephJC

Up next! ☀️📚 We're taking a short break from trials, but don’t go far— #NephJC Summer Book Club is back! We’ll be diving into “Everything is Tuberculosis”—a powerful, thought-provoking read. Join the conversation soon! 📖